Regulators have recommended that the manufacturers should quantify the nitrosamine levels in their drugs and reduce the levels of impurities beyond the said limit. FDA and other regulatory authorities have partnered to share information, inspection reports and communicate effective analytical methods to detect and identify various nitrosamine impurities. This will help develop rapid solutions to ensure the safety and quality of the drug and will also help develop a clear risk assessment strategy for such products.
